Bris­tol My­er­s' com­bo hits a road­block in PhI­II kid­ney test as the search to ri­val Keytru­da con­tin­ues

Bris­tol My­ers Squibb has hit a snag in its Phase III tri­al in­ves­ti­gat­ing the com­pa­ny’s Op­di­vo and Yer­voy com­bo in re­nal cell car­ci­no­ma, or RCC.

Re­searchers had been in­ves­ti­gat­ing Op­di­vo and Yer­voy to­geth­er as a po­ten­tial treat­ment for pa­tients who have un­der­gone a full or par­tial re­moval of their kid­ney and who are at a high­er risk of a re­lapse. But in a re­lease Fri­day, part A of its Phase III study, dubbed Check­Mate -914, “did not meet the pri­ma­ry end­point of dis­ease-free sur­vival,” the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER